Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ: ALVO )

13.40 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 26
Open 13.40
Bid (Size) 13.40 (1)
Ask (Size) 21.30 (1)
Prev. Close 13.40
Today's Range 13.40 - 13.40
52wk Range 6.700 - 18.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
From Alvotech
Via GlobeNewswire
Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday
Via Benzinga

Performance

YTD
+17.96%
+17.96%
1 Month
+0.98%
+0.98%
3 Month
-5.96%
-5.96%
6 Month
+52.97%
+52.97%
1 Year
+49.05%
+49.05%

More News

Read More
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
From Alvotech
Via GlobeNewswire
ALVO Stock Earnings: Alvotech Reported Results for Q4 2023
Via InvestorPlace
Alvotech's Earnings: A Preview
Via Benzinga
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
From Alvotech
Via GlobeNewswire
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Alvotech Announces Increase in Number of Own Shares
From Alvotech
Via GlobeNewswire
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
From Alvotech
Via GlobeNewswire
Earnings Scheduled For March 20, 2024
Via Benzinga
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
From Alvotech
Via GlobeNewswire
Alvotech Appoints Interim Chief Quality Officer
From Alvotech
Via GlobeNewswire
TEVA Stock Pops 4% as Teva Receives FDA Approval
Via InvestorPlace
Exposures Product Safety
Why Is Generic Drugs Player Teva Pharma Stock Trading Higher Today?
Via Benzinga
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
From Alvotech
Via GlobeNewswire
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
From Alvotech
Via GlobeNewswire
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
From Teva Pharmaceutical Industries Limited
Via Business Wire
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
American Airlines To Rally Around 32%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
3 mid-caps under $20 that Wall Street loves
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
From Alvotech
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.